Monograph Details
|
|
Cardiovascular System
> CHF and arrhythmias
|
|
LOPRESSOR |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
β-blocker. |
| Generic Name |
|
Metoprolol tartrate 50mg, 100mg; scored tabs. |
| Indications |
|
In stabilized patients after MI, to reduce mortality. |
| Children |
|
Not recommended. |
| Adults |
|
Early treatment: see literature. Late treatment: 100mg twice a day for at least three months. |
| Contraindications |
|
Significant 1st degree heart block. 2nd- or 3rd-degree AV block. Overt heart failure. Systolic pressure<100mmHg or heart rate <45 beats/min. |
| Precautions |
|
CHF. Bronchospastic disease, COPD. Hepatic dysfunction. Diabetes. Hyperthyroidism. Surgery. SLE. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Bradycardia with catecholamine-depleting drugs. Potentiated by felodipine. May increase cardiac effects of calcium channel blockers, digitalis. Antagonized by NSAIDs, barbiturates, rifampin. May interfere with glaucoma screening tests. May block epinephrine. |
| Adverse Reactions |
|
Fatigue, dizziness, depression, hypotension (discontinue if occurs), diarrhea, rash, dyspnea, bradycardia, cold extremities, palpitations, CHF, peripheral edema, hypotension, bronchospasm, heart block. |
| How Supplied |
|
Tabs—100, 1000 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
